Table 1 Comparison of the preprocedural data between patients who had surgical vs. transcatheter aortic valve replacement before and after matching (SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement)
From: Isolated surgical vs. transcatheter aortic valve replacement: a propensity score analysis
| Â | Unmatched | Matched | ||||
|---|---|---|---|---|---|---|
SAVR (n = 293) | TAVR (n = 496) | p-value | SAVR (n = 53) | TAVR (n = 53) | SMD | |
Age (y) | 51 (34–63) | 77 (71–82) | ˂ 0.001 | 66 (60–72) | 65 (60–70) | 0.11 |
Male | 219 (74.74%) | 303 (61.09%) | ˂ 0.001 | 15 (28.30%) | 19 (35.85%) | −0.16 |
BMI (kg/m2) | 28 (23–33) (n = 291) | 30 (26–34) (n = 496) | ˂ 0.001 | 29 (25–34) | 28 (25–33) | 0.03 |
EuroSCORE II | 1.1 (0.69–1.89) (n = 289) | 2.99 (1.84–5.43) (n = 496) | ˂ 0.001 | 1.37 (0.99–2.52) | 1.57 (1.13–2.37) | 0.14 |
Hypertension | 132/288 (45.83%) | 387/496 (78.02%) | ˂ 0.001 | 37 (69.81%) | 40 (75.47%) | −0.12 |
Diabetes mellitus | 101/287 (35.19%) | 321/496 (64.72%) | ˂ 0.001 | 29 (54.72%) | 34 (64.15%) | −0.19 |
Chronic lung disease | 21/279 (7.53%) | 80/496 (16.13%) | 0.001 | 5 (9.43%) | 7 (13.21%) | −0.12 |
Recent MI | 3/282 (1.06%) | 27/496 (5.44%) | 0.002 | 1 (1.89%) | 0 | 0.19 |
Heart failure (past 2 weeks) | 3/264 (1.14%) | 89/492 (18.09%) | Ë‚ 0.001 | 0 | 0 | 0 |
Stroke | 11/278 (3.96%) | 42/496 (8.47%) | 0.02 | 5 (9.43%) | 5 (9.43%) | 0 |
Atrial fibrillation | 19/280 (6.79%) | 67/496 (13.51%) | 0.004 | 4 (7.55%) | 4 (7.55%) | 0 |
NYHA III/IV | 195 (66.55%) | 421 (84.88%) | Ë‚ 0.001 | 42 (79.25%) | 40 (75.47%) | 0.09 |
Previous cardiac surgery | 48/285 (16.84%) | 64/496 (12.90%) | 0.13 | 8 (15.09%) | 8 (15.09%) | 0 |
Previous PCI | 10/286 (3.50%) | 136/496 (27.42%) | ˂ 0.001 | 3 (5.66%) | 4 (7.55%) | −0.08 |
Hemoglobin (mg/dl) | 13.75 (12.15–15) (n = 292) | 12.2 (11. 13.4) (n = 496) | ˂ 0.001 | 13.4 (12–14.4) | 13 (11.6–13.8) | 0.15 |
Creatinine clearance (mL/min) | 107 (79–136) | 64 (45–82) | ˂ 0.001 | 88 (59–110) | 85 (68–106) | −0.07 |
Ejection fraction (%) | 55 (50–60) (n = 276) | 55 (45–60) (n = 482) | 0.01 | 55 (50–60) | 55 (55–60) | −0.11 |
LVEDD (mm) | 52 (47–58) (n = 276) | 49 (44–53) (n = 482) | ˂ 0.001 | 48 (46–53) | 50 (46–54) | −0.06 |
LVESD (mm) | 35 (29–41) (n = 276) | 33 (27–38) (n = 478) | ˂ 0.001 | 33 (28–37) | 32 (28–37) | 0.10 |
Indexed LV mass (gm/m2) | 123 (99–156) (n = 260) | 115 (98–134) (n = 473) | ˂ 0.001 | 119 (98–137) | 121 (105–144) | 0.17 |
Peak AV gradient (mmHg) | 80 (45–105) (n = 259) | 78 (66–93) (n = 490) | 0.86 | 89 (75–108) | 91 (76–102) | −0.09 |
Grade III/IV AR | 106/260 (40.77%) | 18/443 (4.06%) | Ë‚ 0.001 | 7/49 (14.29%) | 4/46 (8.70%) | 0.17 |
Mod/severe AS | 170/247 (68.83%) | 435/456 (95.39%) | ˂ 0.001 | 39/48 (81.25%) | 46/48 (95.83%) | −0.47 |
Emergency procedure | 13/274 (4.74%) | 8/496 (1.61%) | 0.02 | 1 (1.89%) | 1 (1.89%) | 0 |
Size of the valve (mm) | 21 (20–23) | 26 (26–29) | ˂ 0.001 | 21 (21–23) | 26 (26–29) | −1.52 |